The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet® hydrocodone formulations and compare to a marketed hydrocodone drug.

Outcomes:

Pharmacokinetic parameters and bioequivalence testing.

Inclusion Criteria:

• Non-smokers
• ≥18 and ≤55 years of age
• BMI ≥19 and ≤30.0

Exclusion Criteria:

• Clinically significant abnormalities, physical or psychological illnesses or conditions contraindicating hydrocodone treatment
• History of significant abuse, dependance or addiction of alcohol, drugs or hard drugs within one year prior to screening
• Allergic to hydrocodone, hydromorphone, other opioids, or related drugs
• Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to study drug administration
• Pregnant or breast-feeding